CSTL Stock — Castle Biosciences Inc

Castle Biosciences Inc (CSTL)

Updated October 16, 2026.

CSTL is a Stock. Total return is 49.3% over the past 7.2 years, 133.2 points behind SPY at 182.5%.

Castle Biosciences is a molecular diagnostics company that develops gene expression profile and spatialomics tests for diagnosing and guiding treatment of dermatologic cancers, Barrett's esophagus, atopic dermatitis, and uveal melanoma. The company serves dermatology and gastroenterology markets with products including DecisionDx-Melanoma, TissueCypher, AdvanceAD-Tx, and other diagnostic tests. Castle Biosciences does not currently distribute dividends.

CSTL performance versus SPY

Price and return data through 2026-10-16.

Total return is 49.3% over the past 7.2 years, 133.2 points behind SPY at 182.5%. Over the past year its total return — price change plus distributions reinvested — is 41.9%. Its deepest 1-year drawdown was 57.8%.

CSTL key facts

Asset type

Stock

Asset class

Equity

Inception date

07/25/2019

Distribution frequency

None

Last close

$31.96 (as of 2026-10-16)

Market cap

$976,362,244

Average volume

380930.0

Beta

0.945

Payout ratio

0.0%

EPS

$-0.64

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CSTL risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 57.8%.

Who may consider CSTL — and who may not

It is a weaker fit for investors who need monthly cash flow (CSTL does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on CSTL

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions